SEC Filings

SEC Filings

Filing date	Description	Form	View
Aug 31, 2021	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-21-000116.pdf 0001235802-21-000116.rtf 0001235802-21-000116.xls
Aug 24, 2021	Statement of changes in beneficial ownership of securities	4	View HTML 0001235802-21-000111.pdf 0001235802-21-000111.rtf 0001235802-21-000111.xls
Aug 16, 2021	Report of unscheduled material events or corporate event	8-K	View HTML 0001558370-21-011781.pdf 0001558370-21-011781.rtf 0001558370-21-011781.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Aug 16, 2021	Quarterly report which provides a continuing view of a company's financial position	10-Q	View HTML 0001558370-21-011785.pdf 0001558370-21-011785.rtf 0001558370-21-011785.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jul 19, 2021	Report of unscheduled material events or corporate event	8-K	View HTML 0001104659-21-093258.pdf 0001104659-21-093258.rtf 0001104659-21-093258.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Jun 25, 2021	EFFECT	EFFECT	View HTML 9999999995-21-002522.pdf 9999999995-21-002522.rtf 9999999995-21-002522.xls
Jun 25, 2021	EFFECT	EFFECT	View HTML 9999999995-21-002519.pdf 9999999995-21-002519.rtf 9999999995-21-002519.xls
Jun 25, 2021	EFFECT	EFFECT	View HTML 9999999995-21-002523.pdf 9999999995-21-002523.rtf 9999999995-21-002523.xls
Jun 25, 2021	EFFECT	EFFECT	View HTML 9999999995-21-002524.pdf 9999999995-21-002524.rtf 9999999995-21-002524.xls
Jun 25, 2021	EFFECT	EFFECT	View HTML 9999999995-21-002517.pdf 9999999995-21-002517.rtf 9999999995-21-002517.xls

Data provided by Kaleidoscope.

For investor inquiries, please contact:

ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Contacts:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com

PRINT PAGE

EMAIL PAGE